Spectrum Solutions v. Longhorn Vaccines: Federal Circuit Cross-Appeal Dismissed
Spectrum Solutions LLC voluntarily dismissed five consolidated cross-appeals against Longhorn Vaccines & Diagnostics LLC at the Federal Circuit, covering US9212399B2 — a biological specimen collection and transport system patent. The motion was unopposed and resolved in 180 days, with each party bearing its own costs. Separate Longhorn-initiated appeals (2023-2111 et al.) remain live, with the PTO directed to declare whether it will intervene.
Spectrum’s voluntary exit leaves Longhorn’s core appeals intact
Spectrum Solutions LLC filed five cross-appeals at the Court of Appeals for the Federal Circuit (Appeal Nos. 2024-2361 through -2365), consolidated against corresponding appeals brought by Longhorn Vaccines & Diagnostics LLC (Appeal Nos. 2023-2111 through -2115). The dispute centres on US9212399B2, directed to a biological specimen collection and transport system and method of use — technology relevant to nucleic acid preservation and field-deployable diagnostics.
On 25 March 2025, the Federal Circuit granted Spectrum’s unopposed motion to dismiss all five of its cross-appeals and to withdraw from the remaining proceedings. The five cross-appeal dockets (2024-2361 et al.) were deconsolidated from Longhorn’s original appeals and formally dismissed, with each party bearing its own costs. Critically, this dismissal is procedural: no merits determination was reached on the underlying infringement or validity questions.
The 180-day resolution is notably swift for Federal Circuit proceedings, suggesting the parties reached an understanding — or Spectrum made a strategic decision — prior to substantive briefing. The fact that the motion was unopposed by Longhorn is commercially significant: Longhorn’s own appeals (2023-2111 et al.) continue, and the court has directed the USPTO to advise within 30 days whether it will intervene, signalling that validity questions on US9212399B2 remain squarely before the Federal Circuit.
Filing to Appeal Dismissed in 180 days
180 days — faster than the typical Federal Circuit appeal, resolved procedurally without merits briefing
Cross-appeal dismissed: what the Federal Circuit’s order means for both parties
Unopposed motion to dismiss ends Spectrum’s cross-appeals procedurally
An unopposed motion to dismiss at the Federal Circuit terminates the moving party’s appeals without any merits adjudication. The court does not evaluate the underlying patent claims, infringement allegations, or validity arguments. Spectrum’s withdrawal from Appeal Nos. 2024-2361 through -2365 means no appellate ruling was issued on those specific cross-appeal issues. Longhorn’s parallel appeals (2023-2111 et al.) are expressly preserved and deconsolidated.
Procedural dismissal — no merits rulingSpectrum exits the appellate proceedings — strategic retreat or pragmatic pivot?
By voluntarily dismissing, Spectrum avoids an adverse appellate ruling on its cross-appeal positions, but surrenders any affirmative relief it sought at this level. The unopposed nature of the motion suggests Longhorn did not extract concessions to agree. Spectrum’s ability to pursue any remaining district court remedies or separate proceedings depends on the specific scope of what was waived — a question the public record does not resolve.
Voluntary exit — no concession on recordLonghorn’s core appeals survive; USPTO intervention now pivotal
Longhorn Vaccines retains its active appeals (2023-2111 et al.) before the Federal Circuit, now freed from Spectrum’s cross-appeals. The court has directed the USPTO to declare within 30 days whether it will intervene — a procedural step that could significantly shape the briefing posture and substantive weight of the remaining proceedings. Longhorn’s exposure on US9212399B2 validity and infringement remains unresolved.
Active exposure — USPTO intervention pendingSpecimen collection IP landscape remains unsettled pending Longhorn’s appeals
US9212399B2 covers specimen collection and transport technology with applications in molecular diagnostics, point-of-care testing, and field biosurveillance. With Spectrum’s cross-appeals dismissed but Longhorn’s challenges continuing, the enforceability of this patent remains commercially uncertain. Companies in the diagnostic kit, biospecimen logistics, and nucleic acid preservation sectors should monitor the remaining 2023-2111 proceedings closely before making product or licensing decisions.
Patent enforceability unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Spectrum Solutions, LLC | Company | Biological specimen collection technology company — holder of US9212399B2Search in Eureka ↗ |
| Defendant | Longhorn Vaccines & Diagnostics, LLC | Company | Longhorn Vaccines & Diagnostics LLC — molecular diagnostics and specimen preservation companySearch in Eureka ↗ |
| Plaintiff counsel | Benjamin Bruce Anger | Attorney | Counsel for Spectrum Solutions, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing Spectrum Solutions, LLCSearch in Eureka ↗ |
| Defendant counsel | Christie Corn | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant counsel | David M. Krinsky | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant counsel | John Marcus McNichols | Attorney | Counsel for Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP | Law Firm | Representing Longhorn Vaccines & Diagnostics, LLCSearch in Eureka ↗ |
| Presiding judge | Judge PROST | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order grants Spectrum’s unopposed motion, deconsolidates the five cross-appeal dockets from Longhorn’s parallel series, and dismisses them with a mutual costs bearing. Critically, the phrasing ‘each party shall bear its own costs as to those appeals’ signals a clean procedural exit rather than any negotiated settlement on the merits. The order’s most consequential element may be prospective: the court’s directive to the USPTO to declare intervention intent within 30 days keeps the validity of US9212399B2 in active play before a merits panel through the surviving 2023-2111 appeals.
US9212399B2 — Biological specimen collection and transport system
US9212399B2 (application No. US14/149278) protects a biological specimen collection and transport system and method of use. The patent covers the integrated collection, stabilisation, and transport of biological specimens — most relevantly, technologies that preserve nucleic acids (DNA/RNA) in field or clinical settings without requiring cold-chain logistics. This class of innovation became commercially critical as molecular diagnostics expanded into point-of-care and remote-deployment scenarios, and gained heightened relevance during large-scale infectious disease surveillance programmes.
The patent sits at the intersection of specimen logistics and molecular diagnostics — a sector attracting significant investment following the expansion of PCR-based and nucleic acid amplification testing platforms. Competitors developing specimen collection kits, viral transport media, or integrated sample-to-answer systems should map their claim exposure carefully. The ongoing Federal Circuit proceedings in the 2023-2111 series mean claim scope and validity remain judicially unsettled, creating both risk and opportunity for market participants seeking to design around or licence the technology.
Should you run an FTO against US9212399B2?
Any company developing, manufacturing, or distributing biological specimen collection systems, nucleic acid transport media, or field-deployable diagnostic kits should treat US9212399B2 as an active FTO consideration. The patent’s claims on integrated collection and transport methodology are broad enough to implicate a range of commercial form factors — from swab-based sample kits to liquid biopsy transport systems. With Federal Circuit validity proceedings still live in the 2023-2111 appeals, the risk profile is dynamic: a claim-narrowing outcome could open design space, while an affirmance would reinforce enforcement leverage.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map their product architecture against the claim tree of US9212399B2, identify potential design-around pathways, and monitor the Federal Circuit docket for ruling updates in real time. Eureka’s citation analysis can also surface the prior art landscape Longhorn is likely relying on in the surviving appeals — giving product teams early visibility into which claims face the greatest invalidation risk before committing to a product launch or licensing negotiation.
Run a freedom-to-operate analysis on US9212399B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in biological specimen and molecular diagnostics IP
Federal Circuit patent appeals involving biological specimen collection and nucleic acid preservation technology — cases comparable to Spectrum Solutions v. Longhorn Vaccines.
What this case signals for the molecular diagnostics IP landscape
A procedural dismissal at the Federal Circuit rarely ends the story — here, the real battle over US9212399B2 continues in Longhorn’s surviving appeals.
USPTO intervention signal is a rare and meaningful procedural flag
The Federal Circuit’s directive ordering the USPTO to declare intervention intent within 30 days is uncommon and suggests the court anticipates substantive patent validity questions. When the PTO intervenes, it typically signals the appeal touches on issues of broader patent office policy or claim construction with systemic implications — raising the stakes for the sector beyond this single dispute.
Voluntary dismissal without prejudice language absent — scope of waiver unclear
The order specifies that Spectrum’s cross-appeals are dismissed and each party bears its own costs, but does not explicitly state ‘without prejudice.’ The public record is silent on whether Spectrum retains the right to re-raise these arguments. Counsel advising on downstream licensing or enforcement strategies involving US9212399B2 should treat this ambiguity as an open risk until clarified.
Spectrum v Longhorn — key questions answered
The Federal Circuit granted Spectrum Solutions LLC’s unopposed motion to dismiss its five cross-appeals (Nos. 2024-2361 through -2365) against Longhorn Vaccines & Diagnostics LLC on 25 March 2025. The appeals were deconsolidated from Longhorn’s parallel series (2023-2111 et al.), dismissed without a merits ruling, and each party was ordered to bear its own costs. Longhorn’s own appeals remain active.
The dismissal is purely procedural — no court ruled on the validity or infringement of US9212399B2. The patent’s enforceability remains legally unsettled. Longhorn’s continuing appeals (2023-2111 et al.) at the Federal Circuit may yet affect claim scope or validity, making it premature for competitors to treat this dismissal as a clearance signal.
The Federal Circuit’s order directs the USPTO to advise within 30 days whether it intends to intervene in Appeal Nos. 2023-2111 et al. This is a standard procedural step when appeals involve patent validity challenges decided by the Patent Trial and Appeal Board (PTAB). USPTO intervention typically occurs when the government wishes to defend PTAB’s legal reasoning or when the case raises issues of broader patent office policy.
US9212399B2 covers a biological specimen collection and transport system and method of use. The patent protects integrated technologies for collecting, stabilising, and transporting biological specimens — particularly relevant for nucleic acid (DNA/RNA) preservation in field or clinical settings without cold-chain requirements. It has commercial relevance to molecular diagnostics, PCR testing kits, and point-of-care specimen logistics.
A mutual costs-bearing order at the Federal Circuit level typically indicates a clean procedural exit rather than a negotiated settlement with fee components. Neither party was found to have acted in bad faith or caused unnecessary costs. This structure is consistent with an agreed — or at least non-contested — strategic withdrawal by Spectrum, though the public record does not reveal the commercial rationale behind the decision.
PatSnap Eureka searches patents and litigation data to answer instantly.